News

Releases

8. March, 2022

Successful outcome from trial 0204

Cessatech reports successful outcome of bioavailability trial 0204 Topline results of clinical trial 0204...

Read more

Releases

3. March, 2022

Annual report 2021 published

Cessatech A/S publishes its annual report for the fiscal year 2021. “We managed to...

Read more

Facts

3. March, 2022

Physical restraint of children in 79% of Scandinavian emergency departments

Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...

Read more

Releases

6. January, 2022

Changes to the Board of Directors – welcome to Rachel

Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with...

Read more

Releases

22. December, 2021

Cessatech successfully raises DKK 24.3 million through warrant exercise

During the period 25 November – 16 December 2021, holders of TO 1 have...

Read more

Releases

25. November, 2021

Exercise warrants of series TO1 before 14 Dec

In connection with the Company’s IPO in November/December 2020, Cessatech issued units (shares and...

Read more

Releases

2. November, 2021

First US patent covering CT001

The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11.160.799...

Read more

Media

23. September, 2021

#FEMSNABBA…

https://borsvarlden.com/artiklar/Fem-fr%C3%A5gor-till-Jes-Trygved?fbclid=IwAR0sa-omHrXpxrvnQd87xFDRDWZzVQQsIEr6VH9aY7S8BkLbXNzhL6AnShI

Read more

Releases

20. August, 2021

Cessatech reports first patient dosed in pharmacokinetic trial in children of lead product candidate

Clinical trial 0206 will investigate the pharmacokinetics  in children aged 1-17 undergoing elective surgical...

Read more

Releases

19. August, 2021

Second quarter report Q2-2021 – planning for the pivotal trials

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...

Read more

Releases

29. June, 2021

Cessatech announces new Chairman of the Board – getting ready for the pivotal studies

  The Board of Directors has appointed Adam Steensberg as new Chairman of the...

Read more

Releases

31. May, 2021

Last subject dosed in bioavailability trial 0204 of lead product candidate

Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports...

Read more

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.